Biofarm S.A (BIO) Fair Value & Analysis
Healthcare · RO · Market cap 1.5B RON
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from 1.59 RON to 1.60 RON (+0.6%) since Jun 23, 2026. Share price +2.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.6793 RON – 1.48 RON · fair‑value band 1.00 RON – 2.18 RON · the 1.47 RON price screens below the 1.60 RON fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Biofarm S.A (BIO) currently trades at 1.47 RON, while our model-based Fair Value estimate is 1.60 RON — implying the stock looks roughly 8.8% undervalued today. We read business quality at 79/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Biofarm S.A generated revenue of 317M RON at a net margin of 31.8%. Revenue declined 2.7% year over year. It earns a return on equity of 18.5%. The stock trades on a trailing P/E of 16.4. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescription medicines, food supplements, medical devices, cosmetics, medical devices, and other products. The company also exports its products in Albania, Azerbaijan, Georgia, Jordan, Iraq, Kyrgyzstan, Malta, Republic of Moldova, Serbia, and Hungary. Biofarm S.A. was incorporated in 1921 and is based in Bucharest, Romania.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Biofarm S.A reported revenue of 319M RON in FY2025 versus 239M RON in FY2021, a compound +7.5%/yr. Reported net income was 101M RON in FY2025, compounding +13.6%/yr from FY2021.
Is BIO fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Biofarm S.A (BIO) undervalued?
What is the fair value of BIO?
What is the quality score of BIO?
What is the revenue of Biofarm S.A (BIO)?
What is the net profit margin of BIO?
Does Biofarm S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.